http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 24 Jul 2026 07:47:38 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/NovoCure+Ltd.+%28NVCR%29+PT+Lowered+to+%2432+at+H.C.+Wainwright/26810688.html (Updated - July 24, 2026 7:47 AM EDT) <p>H.C. Wainwright analyst Emily Bodnar lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $32.00 (from $46.00) while maintaining a Buy rating.</p><p>The analyst commented: "Record revenue quarter driven by growth across geographies and all marketed therapies; guidance revised upward. The company reported 2Q26 revenue of $183.6M, consisting of $177M for GBM, $5.4M for NSCLC, and $1.6M for LA-PAC, representing 5.5% QoQ growth, compared to FactSet consensus of -0.8%, and our estimate of -0.2%. Revenue growth was observed in all markets, with a record number of active GBM patients in the US, though http://www.streetinsider.com/Analyst+PT+Change/NovoCure+Ltd.+%28NVCR%29+PT+Lowered+to+%2432+at+H.C.+Wainwright/26810688.html Fri, 24 Jul 2026 07:47:38 -0400 NVCR http://www.streetinsider.com/Analyst+Comments/NovoCure+Ltd.+%28NVCR%29+PT+Lowered+to+%2432+at+H.C.+Wainwright/26810688.html (Updated - July 24, 2026 7:47 AM EDT) <p>H.C. Wainwright analyst Emily Bodnar lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $32.00 (from $46.00) while maintaining a Buy rating.</p><p>The analyst commented: "Record revenue quarter driven by growth across geographies and all marketed therapies; guidance revised upward. The company reported 2Q26 revenue of $183.6M, consisting of $177M for GBM, $5.4M for NSCLC, and $1.6M for LA-PAC, representing 5.5% QoQ growth, compared to FactSet consensus of -0.8%, and our estimate of -0.2%. Revenue growth was observed in all markets, with a record number of active GBM patients in the US, though http://www.streetinsider.com/Analyst+Comments/NovoCure+Ltd.+%28NVCR%29+PT+Lowered+to+%2432+at+H.C.+Wainwright/26810688.html Fri, 24 Jul 2026 07:47:38 -0400 NVCR http://www.streetinsider.com/Analyst+PT+Change/NovoCure+Ltd.+%28NVCR%29+PT+Raised+to+%2420+at+Wedbush/26810780.html Wedbush analyst David Nierengarten raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $20.00 (from $18.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/NovoCure+Ltd.+%28NVCR%29+PT+Raised+to+%2420+at+Wedbush/26810780.html Fri, 24 Jul 2026 07:47:32 -0400 NVCR http://www.streetinsider.com/Analyst+PT+Change/NovoCure+Ltd.+%28NVCR%29+PT+Raised+to+%2420+at+Wells+Fargo/26810209.html Wells Fargo analyst Larry Biegelsen raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $20.00 (from $17.00) while maintaining a Equal Weight rating. http://www.streetinsider.com/Analyst+PT+Change/NovoCure+Ltd.+%28NVCR%29+PT+Raised+to+%2420+at+Wells+Fargo/26810209.html Fri, 24 Jul 2026 06:29:38 -0400 NVCR http://www.streetinsider.com/SEC+Filings/Form++144++++++++NovoCure+Ltd+++++++++++++++++++++++++++Filed+by%3A+Leupin+Nicolas/26808402.html si-local-file:///var/storage/secattach/20260723/26808402.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++NovoCure+Ltd+++++++++++++++++++++++++++Filed+by%3A+Leupin+Nicolas/26808402.html Thu, 23 Jul 2026 16:22:00 -0400 NVCR O.15717088 http://www.streetinsider.com/SEC+Filings/Form++144++++++++NovoCure+Ltd+++++++++++++++++++++++++++Filed+by%3A+Leupin+Nicolas/26808402.html si-local-file:///var/storage/secattach/20260723/26808402.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++NovoCure+Ltd+++++++++++++++++++++++++++Filed+by%3A+Leupin+Nicolas/26808402.html Thu, 23 Jul 2026 16:22:00 -0400 NVCR O.15717088 http://www.streetinsider.com/Earnings/Novocure+%28NVCR%29+Tops+Q2+EPS+by+20c%3B+offers+guidance/26804379.html <p>Novocure (NASDAQ: NVCR) reported Q2 EPS of ($0.13), $0.20 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $183.6 million versus the consensus estimate of $172.72 million.</p><p><strong>GUIDANCE:</strong></p><p>Novocure sees FY2026 revenue of $710-725 million, versus the consensus of $708.7 million.</p><p>For earnings history and earnings-related data on Novocure (NVCR) <a href="http://www.streetinsider.com/ec_earnings.php?q=NVCR">click here</a>.</p> http://www.streetinsider.com/Earnings/Novocure+%28NVCR%29+Tops+Q2+EPS+by+20c%3B+offers+guidance/26804379.html Thu, 23 Jul 2026 07:02:35 -0400 NVCR http://www.streetinsider.com/Guidance/Novocure+%28NVCR%29+Tops+Q2+EPS+by+20c%3B+offers+guidance/26804379.html <p>Novocure (NASDAQ: NVCR) reported Q2 EPS of ($0.13), $0.20 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $183.6 million versus the consensus estimate of $172.72 million.</p><p><strong>GUIDANCE:</strong></p><p>Novocure sees FY2026 revenue of $710-725 million, versus the consensus of $708.7 million.</p><p>For earnings history and earnings-related data on Novocure (NVCR) <a href="http://www.streetinsider.com/ec_earnings.php?q=NVCR">click here</a>.</p> http://www.streetinsider.com/Guidance/Novocure+%28NVCR%29+Tops+Q2+EPS+by+20c%3B+offers+guidance/26804379.html Thu, 23 Jul 2026 07:02:35 -0400 NVCR http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++NovoCure+Ltd++++++++++++++For%3A+Jun+30/26804282.html si-local-file:///var/storage/secattach/20260723/26804282.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++NovoCure+Ltd++++++++++++++For%3A+Jun+30/26804282.html Thu, 23 Jul 2026 07:00:00 -0400 NVCR O.15717088 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++NovoCure+Ltd++++++++++++++For%3A+Jun+30/26804282.html si-local-file:///var/storage/secattach/20260723/26804282.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++NovoCure+Ltd++++++++++++++For%3A+Jun+30/26804282.html Thu, 23 Jul 2026 07:00:00 -0400 NVCR O.15717088 http://www.streetinsider.com/Press+Releases/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html <p class="bwalignc"> Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications </p><p class="bwalignc"> CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU </p><p class="bwalignc"> More than 280 active patients on Optune Pax as of June 30, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its http://www.streetinsider.com/Press+Releases/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html Thu, 23 Jul 2026 07:00:00 -0400 A.06822034 NVCR O.15717088 O.20026344 http://www.streetinsider.com/Press+Releases/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html <p class="bwalignc"> Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications </p><p class="bwalignc"> CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU </p><p class="bwalignc"> More than 280 active patients on Optune Pax as of June 30, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its http://www.streetinsider.com/Press+Releases/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html Thu, 23 Jul 2026 07:00:00 -0400 A.06822034 NVCR O.15717088 O.20026344 http://www.streetinsider.com/Press+Releases/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html <p class="bwalignc"> Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications </p><p class="bwalignc"> CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU </p><p class="bwalignc"> More than 280 active patients on Optune Pax as of June 30, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its http://www.streetinsider.com/Press+Releases/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html Thu, 23 Jul 2026 07:00:00 -0400 A.06822034 NVCR O.15717088 O.20026344 http://www.streetinsider.com/Press+Releases/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html <p class="bwalignc"> Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications </p><p class="bwalignc"> CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU </p><p class="bwalignc"> More than 280 active patients on Optune Pax as of June 30, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its http://www.streetinsider.com/Press+Releases/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html Thu, 23 Jul 2026 07:00:00 -0400 A.06822034 NVCR O.15717088 O.20026344 http://www.streetinsider.com/Business+Wire/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html <p class="bwalignc"> Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications </p><p class="bwalignc"> CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU </p><p class="bwalignc"> More than 280 active patients on Optune Pax as of June 30, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its http://www.streetinsider.com/Business+Wire/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html Thu, 23 Jul 2026 07:00:00 -0400 A.06822034 NVCR O.15717088 O.20026344 http://www.streetinsider.com/Business+Wire/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html <p class="bwalignc"> Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications </p><p class="bwalignc"> CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU </p><p class="bwalignc"> More than 280 active patients on Optune Pax as of June 30, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its http://www.streetinsider.com/Business+Wire/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html Thu, 23 Jul 2026 07:00:00 -0400 A.06822034 NVCR O.15717088 O.20026344 http://www.streetinsider.com/Business+Wire/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html <p class="bwalignc"> Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications </p><p class="bwalignc"> CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU </p><p class="bwalignc"> More than 280 active patients on Optune Pax as of June 30, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its http://www.streetinsider.com/Business+Wire/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html Thu, 23 Jul 2026 07:00:00 -0400 A.06822034 NVCR O.15717088 O.20026344 http://www.streetinsider.com/Business+Wire/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html <p class="bwalignc"> Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications </p><p class="bwalignc"> CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU </p><p class="bwalignc"> More than 280 active patients on Optune Pax as of June 30, 2026 </p> <p> BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its http://www.streetinsider.com/Business+Wire/Novocure+Reports+Second+Quarter+2026+Financial+Results/26804302.html Thu, 23 Jul 2026 07:00:00 -0400 A.06822034 NVCR O.15717088 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NovoCure+Ltd++++++++++++++For%3A+Jul+23/26804308.html si-local-file:///var/storage/secattach/20260723/26804308.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NovoCure+Ltd++++++++++++++For%3A+Jul+23/26804308.html Thu, 23 Jul 2026 07:00:00 -0400 NVCR O.15717088 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NovoCure+Ltd++++++++++++++For%3A+Jul+23/26804308.html si-local-file:///var/storage/secattach/20260723/26804308.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NovoCure+Ltd++++++++++++++For%3A+Jul+23/26804308.html Thu, 23 Jul 2026 07:00:00 -0400 NVCR O.15717088 http://www.streetinsider.com/New+Coverage/JPMorgan+Resumes+NovoCure+Ltd.+%28NVCR%29+at+Neutral/26758776.html <p>JPMorgan analyst Jessica Fye resumes coverage on NovoCure Ltd. (NASDAQ: NVCR) with a Neutral rating and a price target of $17.00.</p><p>The analyst comments: “We are moving to a Neutral rating and establishing a $17 December 2027 price target for NVCR. We see valuation reflecting a maturing GBM business plus the prospect for two near-term launches, particularly the one ongoing in pancreatic cancer, in addition to one coming up in brain mets in NSCLC that could accelerate the top line and help define the path to profitability. We view uptake for Optune Pax in pancreatic cancer as the most important near-term http://www.streetinsider.com/New+Coverage/JPMorgan+Resumes+NovoCure+Ltd.+%28NVCR%29+at+Neutral/26758776.html Mon, 13 Jul 2026 03:15:32 -0400 NVCR http://www.streetinsider.com/Analyst+Comments/JPMorgan+Resumes+NovoCure+Ltd.+%28NVCR%29+at+Neutral/26758776.html <p>JPMorgan analyst Jessica Fye resumes coverage on NovoCure Ltd. (NASDAQ: NVCR) with a Neutral rating and a price target of $17.00.</p><p>The analyst comments: “We are moving to a Neutral rating and establishing a $17 December 2027 price target for NVCR. We see valuation reflecting a maturing GBM business plus the prospect for two near-term launches, particularly the one ongoing in pancreatic cancer, in addition to one coming up in brain mets in NSCLC that could accelerate the top line and help define the path to profitability. We view uptake for Optune Pax in pancreatic cancer as the most important near-term http://www.streetinsider.com/Analyst+Comments/JPMorgan+Resumes+NovoCure+Ltd.+%28NVCR%29+at+Neutral/26758776.html Mon, 13 Jul 2026 03:15:32 -0400 NVCR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NovoCure+Ltd++++++++++++++For%3A+Jun+30++Filed+by%3A+Puri+Michal+Nath/26721370.html si-local-file:///var/storage/secattach/20260701/26721370.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NovoCure+Ltd++++++++++++++For%3A+Jun+30++Filed+by%3A+Puri+Michal+Nath/26721370.html Wed, 01 Jul 2026 16:34:00 -0400 NVCR O.15717088 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NovoCure+Ltd++++++++++++++For%3A+Jun+30++Filed+by%3A+Puri+Michal+Nath/26721370.html si-local-file:///var/storage/secattach/20260701/26721370.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NovoCure+Ltd++++++++++++++For%3A+Jun+30++Filed+by%3A+Puri+Michal+Nath/26721370.html Wed, 01 Jul 2026 16:34:00 -0400 NVCR O.15717088 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NovoCure+Ltd++++++++++++++For%3A+Jun+30++Filed+by%3A+Leonard+Frank+X/26721292.html si-local-file:///var/storage/secattach/20260701/26721292.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NovoCure+Ltd++++++++++++++For%3A+Jun+30++Filed+by%3A+Leonard+Frank+X/26721292.html Wed, 01 Jul 2026 16:32:00 -0400 NVCR O.15717088